The Shijiazhuang Science and Technology Bureau recently issued the “Notice on the 2022 Recognition Results of Shijiazhuang Clinical Medical Research Centers,” announcing the list of recognized clinical medical research centers in Shijiazhuang. The Shijiazhuang Clinical Research Center for Traditional Chinese Medicine (TCM) Rheumatic and Immune Diseases, established with the support of Hebei Yiling Hospital, successfully passed the evaluation and recognition process. It is the only TCM center and the only municipal-level clinical medical research center for rheumatic and immune diseases among the five centers approved this time.
It is reported that, in order to actively align with the national and provincial clinical medical research center construction plans, further strengthen the medical science and technology innovation system, and enhance clinical medical research capabilities and the application of scientific achievements, our hospital applied to establish this center. The center has developed a clinical medical innovation system deeply integrating industry, academia, and research, guided by TCM theory, led by medical institutions, and oriented towards the clinical application of Chinese medicine. Going forward, the center will focus on major rheumatic and immune diseases to improve the diagnosis and treatment of difficult and complex conditions; actively integrate high-quality multidisciplinary resources from regional cooperative units to promote discipline integration; vigorously advance the construction of collaborative network units; establish a biobank and clinical medical database for rheumatic and immune diseases; and conduct randomized controlled trials, clinical experience mining, and other research on TCM treatment of rheumatic and immune diseases. The aim is to clarify the efficacy of TCM treatments for rheumatic diseases and to elucidate their mechanisms through experimental and pharmaceutical research. The center’s development aims to realize the significant guiding value of TCM in the prevention and treatment of rheumatic and immune diseases, foster the translation of influential domestic research achievements, and enhance the influence of integrated Chinese and Western medicine rheumatology disciplines in Shijiazhuang.
In the future, our hospital will further strengthen the management and services of this center, fully leveraging its role in disease diagnosis and treatment technology research, collaborative innovation among medical, research, and industry sectors, clinical outcome translation and promotion, academic exchange, and talent cultivation. This will provide scientific and technological support for the medical development of Shijiazhuang and the construction of a Healthy Shijiazhuang.




